Publications and Posters - Affimed

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

AFM28

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers

Pinto et al.
Trends in Immunology 43(11): 932-46.

link to publication

Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling

Hintzen et al.
Frontiers in Oncology. 2022 Sept 14

link to publication

A Phase 1/2a Dose Escalation Study of AFM24 in Patients With Epidermal Growth Factor Receptor-Expressing (EGFR) Solid Tumors: Results From Phase 1

Anthony El-Khoueiry et al.
ESMO 2022

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

Sasse et al.,
Leuk Lymphoma. 2022; 63: 1871-1878.

link to publication

Natural Killer Cell-Mediated Tumor Cell Elimination is Maintained Following Cryopreservation of Natural Killer Cells Pre-complexed with Innate Cell Engagers

Reusch et al.
Antibody Engin & Thera 2022

Novel bispecific innate cell engager AFM28 for the treatment of CD123-positive acute myeloid leukemia and myelodysplastic syndrome

Jana-Julia Siegler et al.
EHA 2022

The Combination of CD16A/EGFR Innate Cell Engager, AFM24, with SNK01 Autologous Natural Killer Cells in Patients with Advanced Solid Tumors

Anthony El-Khoueiry et al.
ASCO 2022

AFM24 in Combination with Atezolizumab in Patients with Advanced EGFR-Expressing Solid Tumors: Phase 1/2a Study Design and Rationale

Omar Saavedra et al.
ASCO 2022

A Phase 1/2a Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Patients with Advanced Solid Cancers: Study Design and Rationale

Omar Saavedra et al.
ASCO 2022

Analysis of the Longitudinal Effects of AFM24, a CD16A/Epidermal Growth Factor Receptor-Targeting (EGFR) Bispecific Innate Cell Engager, Confirms the Mechanism of Action and Supports the Rationale for Combination Approaches in Patients with EGFR-Expressing Solid Tumors

Gabriele Hintzen et al.
NK2022

1
2
3
4
5
6
7
8
9